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Abstract
Background: Cytopenias are the most common HIV-associated hematological abnormality. Cytopenias have been
associated with several factors including sex, race/ethnicity, geographical location and comorbidities such as
tuberculosis, hepatitis B infection, fever and oral candidiasis. Cytopenias become more prevalent as HIV progresses
and are often fatal. Data from resource-limited settings about the prevalence and correlates of cytopenia are limited.
Therefore we conducted this cross-sectional study to assess the prevalence and correlates of cytopenia among adult
AIDS patients at initiation of HAART in Uganda.
Methods: 400 HIV-infected subjects who were HAART-naïve or on HAART for≤ 6 months were enrolled into the
Multivitamins, HAART and HIV/AIDS Trial. Anemia was defined according to WHO guidelines as any hemoglobin
concentration < 12 g/dl for non-pregnant females and < 13 g/dl for males. Leucopenia and thrombocytopenia
were defined using study site laboratory reference ranges for lack of generally accepted definitions for these 2
cell lines as leucopenia if white blood cell count < 2.75×10
9 cells/litre and thrombocytopenia if platelets < 125×10
9
cells/litre for females and < 156×10
9 cells/litre for males. Univariate and bivariate analyses were done to describe the
patient population and log-binomial regression was used to quantify the correlates of cytopenia.
Results: Sixty five percent of the 400 subjects had at least one form of cytopenia. Anemia occurred in 47.8%,
leucopenia in 24.3%, thrombocytopenia in 8.3%, bicytopenia in 21.9% and only 2 had a pancytopenia. Cytopenia was
more prevalent in females (prevalence ratio [PR]:1.33, 95% confidence interval [CI]:1.12-1.59); CD4 count category 50 to
<200 (PR: 0.75, 95% CI: 0.64 -0.88) and CD4 count category 200 to <350 (PR: 0.74, 95% CI: 0.59 - 0.92) compared to CD4
count category <50; normal BMI (PR: 0.82, 95% CI:0.68-1.00) and overweight BMI (PR: 0.64, 95% CI:0.50- 0.82) compared
to underweight BMI and those with a history or presence of oral candidiasis.
Conclusions: Cytopenias are a frequent complication in HIV-infected adults at initiation of HAART in Uganda.
The presence of any cytopenia was associated with female sex, decreasing CD4 count and decreasing body
mass index. Prospective studies in resource-limited settings on the trend in HIV-related cytopenias are needed.
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Human Immunodeficiency Virus (HIV) infection is asso-
ciated with hematological abnormalities, the most com-
mon manifestation being characterized by reduction in
and impaired function of all blood cell lines: red blood
cells (anemia), white blood cells (leucopenia or neutro-
penia) and platelets (thrombocytopenia) collectively called
cytopenias. Neutropenia is defined by abnormally low
numbers of neutrophils which normally make up 50-70%
of circulating white blood cells. Cytopenias increase in fre-
quency as HIV progresses and are often fatal without
intervention [1-4].
Anemia is the most common cytopenia and its preva-
lence varies with different definitions used and in differ-
ent settings. A systematic review of studies documenting
the prevalence or incidence of anemia in HIV-infected
patient populations reported prevalence rates from 1.3%
to 95% [5]. In Europe and the United States, anemia oc-
curs in about 35-65% of individuals before or at the start
of highly active antiretroviral therapy (HAART) [2,6] and
in Africa and Asia the prevalence ranges from 18% to 77%
[7-9]. In Uganda the DART trial reported a prevalence of
0.7% grade 4 anemia at week 4 in patients initiating triple
combination antiretroviral therapy (ART) [10], Mugisha
et al. found 18.9% anemic HIV-positive subjects in a rural
cohort of HIV-infected and HIV negative adults [11] and
Mukaya et al. reported 64.6% anemic patients attending
the medical emergency ward of Uganda’sn a t i o n a lr e f e r r a l
hospital, Mulago [12]. The presence of anemia has been
associated with faster disease progression and has been
shown to independently predict survival [1,2,13-16]. The
widespread use of highly active antiretroviral therapy
(HAART) has led to significant improvements in patient
survival and more specifically in improvement of anemia
particularly severe anemia irrespective of the use of azido-
thymidine (AZT) in the regimen [2,8,10,17-20]. However,
mild to moderate anemia occurs or persists in some
individuals on long-term therapy and gradually impairs
the individual’s functional status [2,8,21]. This is clinically
significant because anemia affects quality of life which in
the context of HAART has become an increasingly im-
portant treatment goal [22,23].
Data about the prevalence of leucopenia and
thrombocytopenia and factors associated with their pres-
ence in HIV-infected adults is limited. Leucopenia occurs
in 57 to76% of patients with advanced HIV infection
[24-26], neutropenia specifically was found in 44% of
HIV-infected women prior to initiating HAART [27] while
prevalent thrombocytopenia ranges from 7% to about 21%
increasing with the stage of HIV infection [7] [28]. Neu-
tropenia may be caused by adverse drug reactions or mye-
losuppressive drugs [7] and it has been associated with
low baseline CD4 count [29]. Thrombocytopenia has been
independently associated with chronic active hepatitis
B virus infection, male gender, low absolute neutrophil
count and low CD4 count [15, 3 0 ] .H o w e v e r ,as t u d yi n
India did not find a significant correlation between
thrombocytopenia and low CD4 count [7].
Cytopenia in HIV-1 infected adults has been associ-
ated with geographical location (anemia and neutropenia
were highest in Southern African countries and Haiti
compared to the US) [30], race/ethnicity (anemia was
more prevalent in African-Americans [1,31] and neutro-
penia was higher in non-Hispanics than Hispanics [30]),
female sex (anemia and neutropenia were higher in fe-
males) [1,6,9,11,30,31], age (anemia is more prevalent in
older patients compared to younger patients) [6] and la-
boratory markers such as low mean corpuscular volume
(MCV: < 80 femtolitres) [20,31], CD4 cell count (low
CD4 count has been associated with prevalent anemia,
neutropenia and thrombocytopenia) [7,11,29,31], high
viral load [31], use of AZT [31], low body mass index
(BMI) [9,10] and co-morbid conditions such as tubercu-
losis [9,20], hepatitis B (thrombocytopenia was associ-
ated with hepatitis B surface antigen) [30], malaria, fever,
pneumonia and oral candidiasis [11] .
Data about the prevalence and factors associated with
cytopenia in patients initiating HAART has largely been
derived from developed countries that may differ from
developing countries in patient profile, cytopenia eti-
ology, antiretroviral regimen options and comorbidi-
ties [1,2,13,14,19,31,32].
The magnitude of pre-existing cytopenias and associated
factors at the time of initiating HAART could impact on
ART treatment outcomes. However, the magnitude of this
problem has not been adequately described in resource-
limited settings. This cross-sectional study is designed to
fill these gaps by investigating the prevalence and correlates
of cytopenia among adult Ugandan AIDS patients either
HAART-naïve at enrollment or on HAARTfor≤6m o n t h s .
We hypothesize that this population will have higher prev-
alences of each cytopenia and worse clinical parameters
compared to similar cohorts in developed countries. This
analysis was approved by the Infectious Diseases Institute
Scientific Review Committee, and the Higher Degrees, Re-
search and Ethics Committee (HDREC) of the Makerere
School of Public Health.
Methods
Study design, setting and population
In this article we present hematological data which were col-
lected at enrolment into a double blind placebo-controlled
micronutrient trial among HIV-positive adults ≥18 years in
Uganda. The adult HIV prevalence in Uganda is estimated
at 7.3% [33]. Between March 2010 and June 2012, 400 HIV-
positive adults were enrolled into the Multivitamins,
HAART and HIV/AIDS Trial. The inclusion criteria
for enrolment into the parent trial included being at
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and eligible to initiate HAART or have been on HAART
for not more than 6 months at the time of enrolment, liv-
ing within a 20 kilometre radius of the health unit of
enrolment, without an intention of migrating out of
Kampala for at least 18 months after enrolment and
provide informed written consent for participation. To
be eligible for initiation of HAART, subjects had to
present with either WHO stage 4 or CD4 count less
than 200 cells/μl, or WHO stage 3 or CD4 count less
than 350 cells/μl. Women who were pregnant and those
who were ineligible to initiate HAART at the time of en-
rolment due to early-stage disease were excluded from the
trial. Further details of the design and methods of the trial
are described elsewhere [34]. Patients were clinically man-
aged at the Infectious Diseases Institute (IDI), Makerere
University College of Health Sciences and this trial was
implemented at IDI in collaboration with the Makerere
School of Public Health and the Harvard School of Public
Health. All data presented here were collected at baseline,
before the start of the micronutrient intervention.
At enrollment all subjects had a Complete Blood
Count (CBC, Beckman Coulter Act 5 Diff, Miami, Florida,
USA), and CD4 cell count (BD FACSCalibur System, Bec-
ton Dickinson, San Jose, California, USA) done provided
this had not been done within a month prior to enrol-
ment. Blood was collected in an EDTA vacutainer for both
tests.
Measurements
Anemia
Anemia was defined according to WHO guidelines
as <12 g/dl for non-pregnant women and <13 g/dl for
men. Anemia severity was graded as mild: 11–11.9 g/dl
for women and 11–12.9 g/dl for men; moderate: 8–
10.9 g/dl for both sexes; and< 8 g/dl as severe anemia
for both sexes [35].
Other cytopenias
There are no generally accepted cut-offs for other cytope-
nias. A study in India used a cut off of total white blood
cells<4000 cells/μl to define leucopenia and platelet
count <150× 10
3 cells/μl to define thrombocytopenia
in HIV-infected individuals [7]. We used the study site
laboratory reference ranges (Makerere University-John
Hopkins University, MUJHU Core laboratory) to de-
fine leucopenia and thrombocytopenia. The MUJHU
Core-laboratory is a CAP-certified laboratory (CAP certifi-
cate number 7139001). Other cytopenias were thus de-
fined as: leucopenia if total white blood cell count<2.75×
10
9cells/litre, thrombocytopenia if platelet count <125×
10
9 cells/litre for females and <156×10
9 cells/litre for
males; bicytopenia if a subject had a combination of any 2
cytopenias and pancytopenia as having all three forms of
cytopenia simultaneously.
Statistical analysis
Univariate analysis was used to describe the subjects’
characteristics. Continuous variables were summarized
using means or medians as found appropriate and cat-
egorical variables were summarized using frequencies
and percentages. Thus prevalences of the various forms
of cytopenia are reported as percentages of subjects with
cytopenias with the denominator being all subjects in
the trial.
We used the log-binomial regression model to investi-
gate the factors associated with cytopenias in general and
then anemia, leucopenia and thrombocytopenia were con-
sidered as individual outcome variables. Prevalence ratios
(PR) and their 95% confidence intervals (95%CI) are re-
ported. The independent factors investigated included
demographic variables (e.g. sex, age, marital and em-
ployment status, highest level of education attained)
and clinical/laboratory characteristics (e.g. CD4 cell count,
body mass index, presence or history of oral candidiasis,
presence or history of fever, etc.).
Table 1 Characteristics and hematological values of the
study population at baseline
N=400†
Socio-demographic characteristics Value
Female, n (%) 277 (69.3)
Age, mean (±SD) years 36 (9.0)
Married 135 (33.8%)
Employed 345 (82.3)
Education level(completed at least primary)* 387 (96.8%)
Immunological, HAART and nutritional status
CD4 cell count, median (IQR) per μl 142 (1–645)
HAART status at recruitment
On HAART, n (%) 200 (50)
Not yet on HAART, n (%) 200 (50)
Duration on HAART at enrollment, mean (±S.D) months 2.5± 1.6
BMI†, mean±S.D 23.8±9.2
Hematological parameters, median (IQR)
Hemoglobin, g/dl 12.3 (4.9-17.6)
White blood cell count×10
9 per litre 3.4 (1.2-9.9)
Platelets×10
9 per litre 244 (11–616)
Mean corpuscular volume, femtolitres (fl) 86 (58–126)
Red cell Distribution Width (RDW),% 13.6 (9–25.1)
† Data for BMI were missing for 3 participants due to missing weights
at baseline.
*One participant had education level as “unknown”.
S.D = Standard Deviation.
IQR =Inter Quartile Range.
μl = microlitre.
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n % Any Cytopenia % Anemia % Leucopenia % Thrombocytopenia
All participants 400 65.0 47.8 24.3 8.3
Characteristic
Gender
Male 123 56.9 34.1 23.6 14.6
Female 277 68.6 53.8 24.5 5.4
Age
18 to< 30 98 63.3 45.9 23.5 5.1
30 to< 35 80 70.0 50.0 26.3 11.3
35 to< 41 117 64.1 45.3 24.8 8.5
≥ 41 105 63.8 50.5 22.9 8.6
Education level
None 12 66.7 33.3 41.7 8.3
Minimum Primary 206 65.5 48.5 21.8 8.7
Minimum Secondary 141 66.7 50.4 25.5 8.5
Tertiary 40 57.5 40.0 27.5 5.0
Unknown† 1 0.0 0.0 0.0 0.0
Employment status
Unemployed 55 69.1 56.4 20.0 3.6
Employed 345 64.3 46.4 24.9 9.0
Marital status
Not married 265 64.9 49.1 22.3 7.2
Married 135 65.2 45.2 28.1 10.4
CD4 count cells/μl
<50 59 84.7 50.8 52.5 15.3
50 to <200 241 62.2 49.0 20.3 6.6
200 to<350 88 59.1 43.2 15.9 9.1
≥ 350 12 66.7 41.7 25.0 0.0
BMI
under weight 31 83.9 71.0 12.9 9.7
normal 261 66.7 50.2 24.1 8.8
over weight 105 54.3 34.3 25.7 6.7
Incomplete information* 3 100.0 66.7 100.0 0.0
HAART status at recruitment
Not using HAART 200 68.0 47.0 26.0 12.0
AZT-based HAART 15 66.7 60.0 6.7 0.0
Non-AZT based HAART 185 61.6 47.6 23.8 4.9
Presence/history of oral candidiasis
No 305 62.0 44.9 23.3 7.5
Yes 95 74.7 56.8 27.4 10.5
Presence/history of fever
No 195 63.6 44.6 26.7 8.2
Yes 205 66.3 50.7 22.0 8.3
† One participant had education level as “unknown“
*Three participants did not have records for baseline weight therefore BMI could not be computed for these thus categorized as “Incomplete information”.
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Results
Patient characteristics
This analysis included the 400 subjects enrolled in the
parent trial of which 277(69.3%) were female and overall
the mean age of the study population was 36 years
(Table 1). The median CD4 cell count was 142 cells/μl
and 50% of the subjects had initiated antiretroviral ther-
apy at the time of enrolment. The mean duration on
HAART was 2.5 months (±1.6 SD). The mean BMI was
23.8 (SD ±9.2),
Prevalence of cytopenias
A total of 260 (65%) had at least one form of cytopenia.
Anemia was the most common cytopenia occurring in
192 (47.8%) of the subjects followed by leucopenia oc-
curring in 96 (24.3%), thrombocytopenia in 32 (8.3%),
bicytopenia in 88 (21.9%) and only 2 had a pancytopenia
(Table 2). Cytopenias were more prevalent in subjects
aged between 30 to 35 years and in those with CD4
count less than 50 cells/μl.
Factors associated with cytopenias
In this analysis the factors found to be associated with
any cytopenia were female sex, CD4 cell count and body
mass index (Table 3). The prevalence ratio of any cyto-
penia among females compared to males was 1.21 (95%
confidence interval [CI]: 1.01-1.43). The prevalence ratio
(PR) of having any form of cytopenia decreased with in-
creasing CD4 count; for CD4 count category 50 to < 200
cells/μl PR =0.73 [95% CI: 0.63- 0.85, p< 0.001], and for
CD4 count category 200 to <350 PR =0.70 [95% CI:
0.57-0.86]. Similarly the prevalence ratio of having any
form of cytopenia decreased with increasing BMI; for
normal compared to underweight BMI PR = 0.79 [95%
CI: 0.67-0.95] and overweight compared to underweight
BMI PR =0.65 [95%CI: 0.51-0.82, p<0.001]. Anemia was
associated with female sex, decreasing BMI and history
or presence of oral candidiasis (Table 4). The prevalence
ratio of having anemia among females compared to
males was 2.24 [95% CI: 1.44-3.49,p<0.001]. The preva-
lence ratio of having anemia decreased with increasing
CD4 count and increasing BMI although the difference
by CD4 category was not statistically significant. With
respect to BMI the PR for having anemia with a normal
BMI was 0.41[95% CI: 0.18-0.93,p=0.033] and for overweight
BMI PR: 0.21[95%CI: 0.09-0.51,p=0.001]. Thrombocytopenia
was associated with sex, HAART status at the time of enrol-
ment and CD4 count category 50 to < 200 cells/μl( T a b l e5 ) .
The PR of having thrombocytopenia among females com-
pared to males was 0.32 [95% CI: 0.15-0.68, p=0.003]. The
PR of having thrombocytopenia among those on HAART
compared to those who were not yet on HAART at
Table 3 Factors associated with the presence of any
cytopenia
Results of uni- and multivariable log-binomial regression models
Covariate Univariable
(n=400)
Multivariable‡
(n=397*)
PR (95% CI) p value PR (95% CI) p value
Sex
Male 1 1
Female 1.21 (1.01
to 1.43)
0.035 1.33 (1.12
to 1.59)
0.002
CD4 count cells/μl
<50 1 1
50 to<200 0.73 (0.63
to 0.85)
<˂0.001 0.75 (0.64
to 0.88)
<0.001
200 to< 350 0.70 (0.57
to 0.86)
0.001 0.74 (0.59
to 0.92)
0.007
≥ 350 0.79 (0.52
to 1.19)
0.256 0.77 (0.50
to 1.19)
0.245
BMI
under weight 1 1
normal 0.79 (0.67
to 0.95)
0.011 0.82 (0.68
to 1.00)
0.045
over weight 0.65 (0.51
to 0.82)
<0.001 0.64 (0.50
to 0.82)
<0.001
Incomplete
information*
----
Presence/history of oral candidiasis
No 1
Yes 1.21 (1.04
to 1.40)
0.012
HAART status at recruitment
Not using HAART 1
AZT-based HAART 0.98 (0.68
to 1.42)
0.917
Non-AZT based
HAART
0.91 (0.78
to 1.05)
0.193
Age, years
18 to<30 1
30 to<35 1.11 (0.90
to 1.36)
0.341
35 to<41 1.01 (0.83
to 1.24)
0.899
≥ 41 1.01 (0.82
to 1.24)
0.936
Presence/history of fever
No 1
Yes 1.04 (0.90
to 1.21)
0.565
‡Multivariable model only includes the variables where data are shown because all
others were lacking significance.
*Three participants with missing BMI could not be included in the log-binomial
regression model because the outcome did not vary, thus n=397 for
multivariable analysis and for BMI in univariable analysis.
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The only factor associated with the presence of leuco-
penia was CD4 count (Table 6); the PR for CD4 count
category 50 to <200 cells/μl compared to CD4 count cat-
egory <50 cells/μl was 0.23 [95%CI: 0.13-0.42, p <0.001]
and PR for CD4 count 200 to <350 cells/μl compared to
CD4 count category <50 cells/μl was 0.17 [95%CI: 0.08-
0.37, p <0.001].
Discussion
Hematological abnormalities in HIV infected individuals
such as cytopenia and in particular anemia have been
shown to predict disease progression and mortality
[2,13,15,36-39]. The causative role of HIV in vivo in al-
tering the bone marrow microenvironment thus inhibit-
ing hematopoiesis and directly resulting in cytopenia is
uncertain [40-44]. However, cytopenias occur more fre-
quently with advanced HIV or as viral replication per-
sists and patients may present with multiple cytopenias
[3,4,45]. We evaluated the types, frequencies and corre-
lates of cytopenia in HIV-infected adults at initiation of
HAART in an urban cohort in Uganda. A higher preva-
lence of all 3 forms of cytopenia was found in this popu-
lation compared to two other studies in HIV-infected
individuals prior to initiation of HAART; one in Korea
and another, a multicenter study. The prevalence of
anemia was 3% in the Korean study and 11.9% in the mul-
ticenter study; neutropenia occurred in 10% and 14.3% and
thrombocytopenia in 2.4% and 7.2% respectively [30,32].
These differences could be due to different cut-off values
used to define the cytopenias particularly anemia. Further-
more patients with severe forms of anemia for instance
Table 4 Factors associated with the presence of anemia
Results of uni- and multivariable log-binomial regression models
Covariate Univariable
(n= 400)
Multivariable‡
(n=397*)
PR (95% CI) p value PR (95% CI) p value
Sex
Male 1 1
Female 2.24 (1.44
to 3.49)
<0.001 2.97 (1.85
to 4.77)
<0.001
BMI
under weight 1 1
normal 0.41 (0.18
to 0.93)
0.033 0.43 (0.19
to 0.99)
0.048
over weight 0.21 (0.09
to 0.51)
0.001 0.17 (0.07
to 0.41)
<0.001
Incomplete
information*
0.82 (0.07
to 10.20)
0.876 1.69 (0.13
to 21.61)
0.686
CD4 count cells/μl
<50 1
50 to <200 0.93 (0.52
to 1.64)
0.795
200 to <350 0.73 (0.38
to 1.42)
0.361
≥ 350 0.69 (0.20
to 2.42)
0.563
Age, years
18 to< 30 1
30 to< 35 1.18 (0.65
to 2.13)
0.588
35 to< 41 0.98 (0.57
to 1.67)
0.928
≥ 41 1.20 (0.69
to 2.08)
0.516
HAART status at recruitment
Not using HAART 1
AZT-based HAART 1.69 (0.58
to 4.93)
0.336
Non-AZT based
HAART
1.02 (0.69
to 1.53)
0.911
Education level
None 1
Minimum Primary 1.89 (0.55
to 6.46)
0.312
Minimum
Secondary
2.03 (0.58
to 7.04)
0.265
Tertiary 1.33 (0.34
to 5.18)
0.678
Unknown† --
Employment status
Unemployed 1
Employed 0.67 (0.38
to 1.19)
0.170
Table 4 Factors associated with the presence of anemia
(Continued)
Marital status
Not married 1
Married 0.86 (0.56
to 1.30)
0.464
Presence/history of oral candidiasis
No 1
Yes 1.62 (1.01
to 2.57)
0.043
Presence/history
of fever
No 1
Yes 1.28 (0.86
to 1.89)
0.221
‡Multivariable model only includes variables for which data are shown below
because all others were lacking significance.
†One participant with unknown education level was excluded from analysis
because the outcome did not vary in this stratum. *Three subjects with
missing BMI could not be not included in the log-binomial regression model
because the outcome did not vary, thus n=397 for the multivariable analysis
and for the BMI univariable analysis.
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under-estimated the true prevalence. Female sex, increas-
ing immune suppression (measured by CD4 cell count)
and decreasing body mass index (BMI) were independent
predictors of having a cytopenia in this study. This is con-
sistent with other studies that have found females to be
more likely to have anemia (as a result of additional de-
mands during pregnancy and menstrual loss) [9,11,30]
and to have a higher odds of neutropenia than males [30].
This study also confirms the findings of other studies that
have shown an association between low CD4 counts and
the presence or development of anemia [6,31], neutro-
penia [29,39] and thrombocytopenia [39]. Furthermore,
the highest rates of cytopenia occurred in patients with
advanced HIV (CD4 count <200 cell/μl) which is consist-
ent with other studies in developing countries [7,9,15,29].
Out of 191 subjects with anemia in our study, 77% (n=
148) had CD4 count <200. Similarly out of 97 subjects
with leucopenia, 82% (n =80) had CD4< 200 and of
the 33 subjects with thrombocytopenia, 75% (n=25)
had CD4 count <200. However, these differences by
CD4 category <200 or≥ 200 were not statistically sig-
nificant. The association of low CD4 cell count with
anemia and leucopenia may be due to the dysregulatory ef-
fect of HIV on the function of early hematopoietic progeni-
tor cells through the viral accessory protein Negative factor
(Nef) [3]. Anemia was the most prevalent cytopenia and fe-
male sex and decreasing BMI were the sole predictors of
having anemia in this study. The prevalence of anemia was
considerably higher compared to a rural Ugandan cohort
which found 18.9% anemic HIV-positive individuals even
though lower hemoglobin cut-offs were used in the rural
Table 5 Factors associated with the presence of
thrombocytopenia
Results of uni- and multivariable log-binomial regression models
Covariate Univariable (n= 400) Multivariable‡
(n=397*)
PR (95% CI) p value PR (95% CI) p value
Sex
Male 1 1
Female 0.33 (0.16
to 0.69)
0.003 0.32 (0.15
to 0.68)
0.003
HAART status at recruitment
§
Not on HAART 1 1
On HAART 0.35 (0.16
to 0.76)
0.009 0.32 (0.14
to 0.75)
0.008
CD4 count cells/μl
<50 1
50 to< 200 0.40 (0.17
to 0.95)
0.037
≥ 200** 0.48 (0.18
to 1.33)
0.159
BMI
under weight 1
normal 0.90 (0.25
to 3.20)
0.873
over weight 0.67 (0.16
to 2.75)
0.575
Incomplete
information*
--
Age, years
18 to< 30 1
30 to< 35 2.36 (0.76
to 7.34)
0.139
35 to< 41 1.74 (0.57
to 5.27)
0.328
≥ 41 1.74 (0.56
to 5.40)
0.335
Education level
None 1
Minimum Primary 1.05 (0.13
to 8.63)
0.961
Minimum
Secondary
1.02 (0.12
to 8.62)
0.983
Tertiary 0.58 (0.05
to 7.00)
0.667
Don’t know - -
Employment status
Unemployed 1
Employed 2.62 (0.61
to 11.3)
0.196
Marital status
Not married 1
Table 5 Factors associated with the presence of
thrombocytopenia (Continued)
Married 1.50 (0.73
to 3.09)
0.274
Presence/history of oral candidiasis
No 1
Yes 1.44 (0.66
to 3.15)
0.358
Presence/history
of fever
No 1
Yes 1.01 (0.50
to 2.06)
0.975
‡Multivariable model only includes variables for which data are shown below
because all others were lacking significance.
§All participants on HAART were categorized into one group for this analysis
because none of the 15 patients on AZT had thrombocytopenia.
AZT = azidothymidine or zidovudine.
*Three participants with missing BMI could not be included in the log-binomial
regression model because the outcome did not vary in this group.
**CD4 categories 200 to <350 and≥ 350 were combined for this analysis
because none of the participants with CD4 count ≥350
had thrombocytopenia.
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cohorts [11]. This could be due to differences in modifiable
factors like types of diet, alcohol consumption, cigarette
smoking and so on which may vary between urban and
rural populations however, we could not confirm this. Sub-
baraman et al. attributed the association between low BMI
and anemia to nutrient deficiencies and chronic malnutri-
tion which is prevalent in resource-limited settings [9]. A
study in Brazil found a lower prevalence of anemia (37.7%)
compared to our study and this was partly attributed to im-
provements in the country’s social and nutritional condi-
tions over recent decades [15]. The etiology of anemia in
HIV-infection is multifactorial and has been attributed to
infiltrative conditions of the bone marrow (e.g. neoplasms,
drugs or infections including HIV itself) [16,46], hemolytic
causes (e.g. red blood cell autoantibodies [47], drugs [48]),
decreased production of or response to endogenous erythro-
poietin [49] and nutritional deficiencies [50]. Without inter-
vention, anemia can lead to significant symptoms like
fatigue, breathlessness, difficulty in concentration and other
effects on functionality and quality of life therefore treat-
ment of anemia in HIV should be aimed at correcting the
underlying cause [16]. Regarding leucopenia, neutropenia is
the most clinically relevant subtype because it is a good indi-
cator of the risk of infection. In this study, decreasing CD4
count was the sole predictor of having leucopenia. The pres-
ence of neutropenia in HIV infection exacerbates the sus-
ceptibility to infections such as bacteremia, meningitis but
particularly to invasive fungal infections [51]. The etiology of
neutropenia is multifactorial and correction of potentially re-
versible causes is critical to management of HIV-associated
Table 6 Factors associated with the presence of
leucopenia
Results of uni- and multivariable log-binomial regression models
Covariate Univariable (n=400) Multivariable‡
(n=397*)
PR (95% CI) p
value
PR (95%
CI)
p
value
CD4 count cells/μl
<50 1 1
50 to <200 0.23 (0.13
to 0.42)
<0.001 0.23 (0.13
to 0.42)
<0.001
200 to <350 0.17 (0.08 to
0.37)
<0.001 0.17 (0.08
to 0.37)
<0.001
≥ 350 0.30 (0.07
to 1.22)
0.094 0.30 (0.07
to 1.22)
0.094
Sex
Male 1
Female 1.05 (0.64
to 1.74)
0.834
Age, years
18 to< 30 1
30 to< 35 1.16 (0.59
to 2.30)
0.669
35 to< 41 1.07 (0.57
to 2.01)
0.822
≥ 41 0.97 (0.50
to 1.86)
0.918
BMI*
under weight 1
normal 2.15 (0.72
to 6.37)
0.168
over weight 2.34 (0.75
to 7.29)
0.144
Incomplete
information*
--
HAART status at recruitment
Not using HAART 1
AZT-based
HAART
0.20 (0.03
to 1.58)
0.128
Non-AZT based
HAART
0.89 (0.56
to 1.41)
0.616
Education level
None 1
Minimum
Primary
0.39 (0.12
to 1.29)
0.124
Minimum
Secondary
0.48 (0.14
to 1.61)
0.234
Tertiary 0.53 (0.14
to 2.03)
0.355
Don’t know
† --
Employment status
Unemployed 1
Employed 0.430
Table 6 Factors associated with the presence of
leucopenia (Continued)
1.33 (0.66
to 2.69)
Marital status
Not married 1
Married 1.37 (0.85
to 2.20)
0.195
Presence/history of oral candidiasis
No 1
Yes 1.24 (0.74
to 2.10)
0.417
Presence/history of
fever
No 1
Yes 0.77 (0.49
to 1.22)
0.272
‡Multivariable model only includes variables for which data are shown below
because all others were lacking significance.
*Three participants with missing BMI could not be included in the log-binomial
regression model because the outcome did not vary in this group.
†One participant with unknown education level was excluded from analysis
because the outcome did not vary in this stratum.
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observed than anemia and leucopenia in our study and this
is comparable to findings in other studies [30,32]. Being fe-
male PR 0.32 [95% CI: 0.15-0.68, p=0.003] and being on
HAART at the time of enrolment PR 0.32 [95% CI: 0.14-
0.75, p =0.008] were associated with decreased odds of hav-
ing thrombocytopenia. Thrombocytopenia is caused
mainly by inadequate platelet production or immune-
mediated platelet destruction [16]. Of the 400 subjects,
200 (50%) were already on HAART at the time of en-
rolment and 93% of these were on an AZT-based regi-
men. AZT has been shown to be the treatment of
choice for HIV-related thrombocytopenia [52]and this
could explain the relatively low prevalence of this cyto-
penia found in our study. However, because abnormal
bleeding in these patients is not very common (i.e. when
platelet counts are>30,000×10
9/L) [53], treatment of
mild to moderate HIV-related thrombocytopenia may not
be necessary [16,53,54].
The main limitation of this analysis is its cross-sectional
design which makes determination of temporal relation-
ships between cytopenias and associated factors difficult.
Furthermore we did not assess the various causes of cyto-
penia and specifically anemia in this population.
Conclusion
In conclusion, this study provides an opportunity to com-
pare the prevalence estimates and correlates of all forms of
cytopenia in HIV-infected adults at initiation of HAART in
Uganda. The prevalence of anemia was the highest and
meets WHO criteria for a severe public health problem. Fe-
male sex, decreasing CD4 count and decreasing BMI were
the main factors associated with having cytopenia. Pro-
spective studies in resource-limited settings on the trend in
hematological parameters are needed. Hematological pa-
rameters are potential markers for disease progression and
treatment outcomes in HAART-treated individuals in these
settings.
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